164 related articles for article (PubMed ID: 32208772)
1. 2-Thiopyrimidine/chalcone hybrids: design, synthesis, ADMET prediction, and anticancer evaluation as STAT3/STAT5a inhibitors.
Lamie PF; Philoppes JN
J Enzyme Inhib Med Chem; 2020 Dec; 35(1):864-879. PubMed ID: 32208772
[TBL] [Abstract][Full Text] [Related]
2. 1,3,4-oxadiazole/chalcone hybrids: Design, synthesis, and inhibition of leukemia cell growth and EGFR, Src, IL-6 and STAT3 activities.
Fathi MAA; Abd El-Hafeez AA; Abdelhamid D; Abbas SH; Montano MM; Abdel-Aziz M
Bioorg Chem; 2019 Mar; 84():150-163. PubMed ID: 30502626
[TBL] [Abstract][Full Text] [Related]
3. Design and synthesis of novel quinoline/chalcone/1,2,4-triazole hybrids as potent antiproliferative agent targeting EGFR and BRAF
Mohassab AM; Hassan HA; Abdelhamid D; Gouda AM; Youssif BGM; Tateishi H; Fujita M; Otsuka M; Abdel-Aziz M
Bioorg Chem; 2021 Jan; 106():104510. PubMed ID: 33279248
[TBL] [Abstract][Full Text] [Related]
4. Synthesis, EGFR Inhibition and Anti-cancer Activity of New 3,6-dimethyl-1-phenyl-4-(substituted-methoxy)pyrazolo[3,4-d] pyrimidine Derivatives.
Bakr RB; Mehany ABM; Abdellatif KRA
Anticancer Agents Med Chem; 2017; 17(10):1389-1400. PubMed ID: 28270084
[TBL] [Abstract][Full Text] [Related]
5. Application of the dual-tail approach for the design and synthesis of novel Thiopyrimidine-Benzenesulfonamide hybrids as selective carbonic anhydrase inhibitors.
Abdel-Mohsen HT; El Kerdawy AM; Omar MA; Petreni A; Allam RM; El Diwani HI; Supuran CT
Eur J Med Chem; 2022 Jan; 228():114004. PubMed ID: 34847409
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis, and molecular docking of novel pyrazole-chalcone analogs of lonazolac as 5-LOX, iNOS and tubulin polymerization inhibitors with potential anticancer and anti-inflammatory activities.
Ahmed AHH; Mohamed MFA; Allam RM; Nafady A; Mohamed SK; Gouda AE; Beshr EAM
Bioorg Chem; 2022 Dec; 129():106171. PubMed ID: 36166898
[TBL] [Abstract][Full Text] [Related]
7. Design, Synthesis, In Vitro Anti-cancer Activity, ADMET Profile and Molecular Docking of Novel Triazolo[3,4-a]phthalazine Derivatives Targeting VEGFR-2 Enzyme.
El-Helby AA; Sakr H; Ayyad RRA; El-Adl K; Ali MM; Khedr F
Anticancer Agents Med Chem; 2018; 18(8):1184-1196. PubMed ID: 29651967
[TBL] [Abstract][Full Text] [Related]
8. Design, synthesis and biological evaluation of novel imidazole-chalcone derivatives as potential anticancer agents and tubulin polymerization inhibitors.
Rahimzadeh Oskuei S; Mirzaei S; Reza Jafari-Nik M; Hadizadeh F; Eisvand F; Mosaffa F; Ghodsi R
Bioorg Chem; 2021 Jul; 112():104904. PubMed ID: 33933802
[TBL] [Abstract][Full Text] [Related]
9. New thieno[3,2-d]pyrimidine-based derivatives: Design, synthesis and biological evaluation as antiproliferative agents, EGFR and ARO inhibitors inducing apoptosis in breast cancer cells.
Farghaly AM; AboulWafa OM; Baghdadi HH; Abd El Razik HA; Sedra SMY; Shamaa MM
Bioorg Chem; 2021 Oct; 115():105208. PubMed ID: 34365057
[TBL] [Abstract][Full Text] [Related]
10. Novel potent substituted 4-amino-2-thiopyrimidines as dual VEGFR-2 and BRAF kinase inhibitors.
Abdel-Mohsen HT; Omar MA; El Kerdawy AM; Mahmoud AEE; Ali MM; El Diwani HI
Eur J Med Chem; 2019 Oct; 179():707-722. PubMed ID: 31284081
[TBL] [Abstract][Full Text] [Related]
11. EGFR inhibitors and apoptotic inducers: Design, synthesis, anticancer activity and docking studies of novel xanthine derivatives carrying chalcone moiety as hybrid molecules.
Abou-Zied HA; Youssif BGM; Mohamed MFA; Hayallah AM; Abdel-Aziz M
Bioorg Chem; 2019 Aug; 89():102997. PubMed ID: 31136902
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and biological evaluation of novel ligustrazine-chalcone derivatives as potential anti-triple negative breast cancer agents.
Luo Y; Wu W; Zha D; Zhou W; Wang C; Huang J; Chen S; Yu L; Li Y; Huang Q; Zhang J; Zhang C
Bioorg Med Chem Lett; 2021 Sep; 47():128230. PubMed ID: 34186178
[TBL] [Abstract][Full Text] [Related]
13. Design and synthesis of some new 6-bromo-2-(pyridin-3-yl)-4-substituted quinazolines as multi tyrosine kinase inhibitors.
Farouk AKBAW; Abdelrasheed Allam H; Rashwan E; George RF; Abbas SE
Bioorg Chem; 2022 Nov; 128():106099. PubMed ID: 35994884
[TBL] [Abstract][Full Text] [Related]
14. Design, Synthesis, biological Evaluation, and molecular docking studies of novel Pyrazolo[3,4-d]Pyrimidine derivative scaffolds as potent EGFR inhibitors and cell apoptosis inducers.
Sherbiny FF; Bayoumi AH; El-Morsy AM; Sobhy M; Hagras M
Bioorg Chem; 2021 Nov; 116():105325. PubMed ID: 34507234
[TBL] [Abstract][Full Text] [Related]
15. New 1,3,4-oxadiazole-chalcone/benzimidazole hybrids as potent antiproliferative agents.
Hagar FF; Abbas SH; Abdelhamid D; Gomaa HAM; Youssif BGM; Abdel-Aziz M
Arch Pharm (Weinheim); 2023 Feb; 356(2):e2200357. PubMed ID: 36351754
[TBL] [Abstract][Full Text] [Related]
16. Novel Pyrazolo[3,4-d]pyrimidines as Potential Cytotoxic Agents: Design, Synthesis, Molecular Docking and CDK2 Inhibition.
Maher M; Kassab AE; Zaher AF; Mahmoud Z
Anticancer Agents Med Chem; 2019; 19(11):1368-1381. PubMed ID: 31038080
[TBL] [Abstract][Full Text] [Related]
17. Discovery of thieno[2,3-d]pyrimidine-based derivatives as potent VEGFR-2 kinase inhibitors and anti-cancer agents.
El-Metwally SA; Abou-El-Regal MM; Eissa IH; Mehany ABM; Mahdy HA; Elkady H; Elwan A; Elkaeed EB
Bioorg Chem; 2021 Jul; 112():104947. PubMed ID: 33964580
[TBL] [Abstract][Full Text] [Related]
18. Pyrazolo[3,4-d]pyrimidine-based dual EGFR T790M/HER2 inhibitors: Design, synthesis, structure-activity relationship and biological activity as potential antitumor and anticonvulsant agents.
Lamie PF; El-Kalaawy AM; Abdel Latif NS; Rashed LA; Philoppes JN
Eur J Med Chem; 2021 Mar; 214():113222. PubMed ID: 33545637
[TBL] [Abstract][Full Text] [Related]
19. Thieno[2,3-d]pyrimidin-4(3H)-one Derivatives of Benzimidazole as Potential Anti- Breast Cancer (MDA-MB-231, MCF-7) Agents.
Dimov S; Mavrova AT; Yancheva D; Nikolova B; Tsoneva I
Anticancer Agents Med Chem; 2021; 21(11):1441-1450. PubMed ID: 32698751
[TBL] [Abstract][Full Text] [Related]
20. Design, synthesis, molecular docking, anticancer evaluations, and in silico pharmacokinetic studies of novel 5-[(4-chloro/2,4-dichloro)benzylidene]thiazolidine-2,4-dione derivatives as VEGFR-2 inhibitors.
El-Adl K; El-Helby AA; Sakr H; Ayyad RR; Mahdy HA; Nasser M; Abulkhair HS; El-Hddad SSA
Arch Pharm (Weinheim); 2021 Feb; 354(2):e2000279. PubMed ID: 33073374
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
